Donanemab and lecanemab have both been proven to slow the progress of the memory-robbing illness in its early stages. They are expected to be approved this year.Donanemab and lecanemab have both been proven to slow the progress of the memory-robbing illness in its early stages. They are expected to be approved this year.Read MoreHealth News | Mail Online
![](https://ourbodyhealth.info/wp-content/uploads/2024/06/85970759-0-image-m-12_1718204950063-XNwymT.jpeg)